We are live on ! Find out more
EVOK

Evoke Pharma
EVOK

Delisted

EVOK was delisted on the 16th of December, 2025.

Back to rankings

7 hedge funds and large institutions have $1.16M invested in Evoke Pharma in 2013 Q4 according to their latest regulatory filings, with 7 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
7
Holders Change
+7
Holders Change %
–
% of All Funds
0.2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
LMF
LMR Master Fund
Cayman Islands
+$397K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$361K
3
Bank of America
Bank of America
North Carolina
+$344K
4
Morgan Stanley
Morgan Stanley
New York
+$183K
5
TC
TFS Capital
Pennsylvania
+$146K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
LMF
1
LMR Master Fund
Cayman Islands
$297K +$397K +277 New
Vanguard Group
2
Vanguard Group
Pennsylvania
$270K +$361K +252 New
Bank of America
3
Bank of America
North Carolina
$258K +$344K +240 New
Morgan Stanley
4
Morgan Stanley
New York
$137K +$183K +128 New
TC
5
TFS Capital
Pennsylvania
$110K +$146K +102 New
ARTA
6
A.R.T. Advisors
New York
$83K +$112K +78 New
U
7
UBS
Switzerland
$6K +$8.6K +6 New

EVOK Hedge Fund Activity: Q4 2013 in Review

7 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q4 2013, worth a combined $1.16M.

Buyers outnumbered sellers: 7 funds opened new EVOK positions and 0 closed out — a net gain of 7 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was LMR Master Fund, opening a new position worth an estimated $397K.

  • 7 institutional investors held Evoke Pharma (EVOK) as of Q4 2013, up from 0 in Q3 2013.
  • Funds reported $1.16M of Evoke Pharma stock for Q4 2013.
  • 7 funds opened new Evoke Pharma positions in Q4 2013 and 0 closed out, a net change of +7 holders.
  • The largest Evoke Pharma buyer in Q4 2013 was LMR Master Fund, an estimated $397K added.

Based on aggregated 13F filings for Q4 2013.